4 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2237419/phibro-pahc-appears-well-poised-on-launches-vaccine-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2237419
Mar 07, 2024 - Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
zc:-7444438580819497867
0
https://www.zacks.com/stock/news/2226352/what-makes-phibro-pahc-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2226352
Feb 14, 2024 - Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zc:-2767039145509108688
0
https://www.zacks.com/stock/news/2222992/phibro-pahc-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2222992
Feb 07, 2024 - Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:-2715959859855452498
0
https://www.zacks.com/stock/news/2221839/medical-products-stocks-earnings-due-on-feb-7-ste-pahc-nvst?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221839
Feb 06, 2024 - Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how STE, PAHC and NVST fare this time.
zc:-3564055900211556282
0